Page 1

Recursion Recursion Reports Second Quarter 2021 Financials and Provides Business Updates August 13 , 2021 - Expanded the total number of research and development programs from 37 to 48 - Announced first internally - developed NCE is advancing to IND - enabling studies - Planning to expand operations to Canada , with Toronto serving as a multidisciplinary hub - Formed Therapeutics Advisory Board chaired by Joseph Miletich , MD , PhD SALT LAKE CITY , Aug. 13 , 2021 / PRNewswire / -- Recursion ( Nasdaq : RXRX ) , a clinical - stage biotechnology company decoding biology by integrating technological innovations across biology , chemistry , automation , data science , and engineering , today reported financial results and business updates for its second quarter ending June 30 , 2021 . " We are excited with how Recursion is expanding across many fronts in order to deliver on our mission to decode biology to radically improve lives , " said Recursion Co - Founder & CEO Chris Gibson , PhD . " Not only is the company continuing to advance and expand the total number of its research and development programs , but we are expanding our operations to Canada to grow our capabilities and workforce and we are enhancing our expertise in research and development by forming a Therapeutics Advisory Board . Moreover , the company continues to build on its medicinal chemistry expertise , resulting in our first internally - developed new chemical entity being advanced to IND - enabling studies for potential treatment of C. difficile colitis . " Stage of Development CLINICAL PRECLINICAL LATE DISCOVERY NEUROINFLAMMATION C ) EARLY DISCOVERY оо 4 PROGRAMS Neuroscience 5 TOTAL PROGRAMS NEUROFIBROMATOSIS TYPE 2 ( NF2 ; est . 3 ) New Chemical Entity Known Chemical Entity FAMILIAL ADENOMATOUS POLYPOSIS ( APC est 50K ) CEREBRAL CAVERNOUS MALFORMATION ( CCM 360K ) O Early Discovery Program 8080 IMMUNE CHECKPOINT RESISTANCE ONCOLOGY C HEPATOCELLULAR CARCINOMA CANCER IMMUNOTHERAPY TARGET ALPHA CANCER IMMUNOTHERAPY TARGET BETA OOO 0000 00000 12 PROGRAMS Oncology 18 TOTAL PROGRAMS GM2 GANGLIOSIDOSIS ( HEXA / HEXR est 400 ) 8 PULMONARY ARTERIAL HYPERTENSION AMPR ) CMT TYPE 2A μα και 150 BATTEN DISEASE O O 4 PROGRAMS 889 CLOSTRIDIUM DIFFICILE COLITIS SENOLYTICS ( M 1 PROGRAM Rare Disease Other 10 TOTAL PROGRAMS 3 TOTAL PROGRAMS Therapeutic Area 000 0000 00000 12 PROGRAMS Inflammation & Immunology 12 TOTAL PROGRAMS EUS is defined as France , Germany , Italy , Spain and the UK . ( 1 ) Our program has the potential to address a number of indications within neuroinflammation , including multiple neurodegenerative diseases totalling at least 13 million patients in the US and EUS . ( 2 ) 730,000 annual incidence in US and EUS . ( 3 ) Annual US and EUS prevalence ( 4 ) Worldwide prevalence ( 5 ) Annual US and EUS incidence for all NF2 - driven meningiomas . ( 6 ) Our program has the potential to address a number of indications driven by MYC alterations , totalling 120,000 patients in the US and EUS annually . We have not finalized a target product profile for a specific indication . ( 7 ) Hereditary and sporadic symptomatic population . Recursion finished the second quarter of 2021 with a portfolio of 4 clinical stage programs , 4 preclinical programs , 7 late discovery programs , and 33 early discovery programs , for a total of 48 research and development programs . Additionally , Recursion continued scaling the total number of executed phenomic experiments to over 82 million , the size of its proprietary data universe to approximately 9 petabytes , and the number of biological inferences to over 179 billion . Data have been generated across 37 human cell types , an in - house chemical library of over 706 thousand compounds , an in silico library of over 12 billion small molecules , and a growing team of more than 270 Recursionauts that is balanced between life scientists and computational and technical experts . The power of the Recursion OS is exemplified by the breadth of active research and development programs . Summary of Business Highlights